Name:           

Candidate number:

Theme: Chronic Myeloid Leukaemia

 

OPTION LIST

 

A

BCR/ABL [t(9;21)]

I

Neutropenia

B

Bacterial septicaemia

J

Raised serum B12

C

BCR/ABL [t(9;22)]

K

Rapid onset

D

Blast crisis

L

Splenomegaly

E

Hairy Cells

M

Trisomy 21

F

Hypercellular bone marrow

 

 

G

Increased myeloid cells

 

 

H

Manhattan Chromosome

 

 

 

 

For each scenario below, choose the most appropriate feature Leukaemia from the list above. Each option may be used once, more than once or not at all.

 

1.         Absence of this feature occurs in less than 20% of Chronic Myeloid Leukaemia cases and is associated with a worse prognosis.

 

 

2.         More often associated with Chronic Lymphocytic Leukaemia

 

 

3.         Imatinib (trade name Glivec®) may be used in the treatment of CML due to its effect on this feature.

 

 

4.         In untreated patients this is more likely to occur.

 

 

5.         Prior use of Imatinib makes management of this feature difficult.

 

 

 

ANSWERS

1.       C         

2.        I

3.        C

4.        D

5.        D